肺活量計市場- 按產品（設備、軟體、消耗品和配件）、技術（峰值流量計、容量和流量測量）、應用（氣喘、慢性阻塞性肺病、囊性和肺纖維化）、最終用途（醫院、居家照護） - 全球預測, 2024 - 2032

由於慢性阻塞性肺病 (COPD)、氣喘和囊性纖維化等呼吸系統疾病盛行率的不斷上升，肺活量計市場規模從 2024 年到 2032 年的複合年成長率可能超過 9.6%。根據世界衛生組織的數據，慢性阻塞性肺病每年奪走超過 300 萬人的生命。隨著全球對呼吸系統疾病早期檢測和管理重要性的認知不斷提高，醫療保健提供者擴大採用肺活量計作為重要的診斷工具。此外，全球人口老化正在促進市場成長，因為老年人更容易患呼吸系統疾病，需要定期監測肺功能。

此外，對預防性醫療保健和健康計劃的日益重視正在促進肺活量測定法測試作為各種醫療保健環境中的常規篩檢工具的採用。將肺活量測定法整合到遠距醫療平台和電子健康記錄中，有助於遠端監控和資料管理，從而提高患者護理和治療效果。旨在改善呼吸保健基礎設施和促進早期疾病檢測的政府措施和醫療保健政策也將有助於推動市場成長。

肺活量計產業根據產品、技術、應用、最終用途和地區進行分類。

從應用來看，到2032年，肺纖維化領域的市場規模將達到9.7%的成長率。肺量計是評估肺纖維化患者的肺功能和監測疾病進展的重要診斷工具。隨著人們越來越認知到定期肺功能檢測在疾病管理中的重要性，專門從事呼吸護理的醫療保健提供者對肺活量計的需求將繼續上升。

就最終用途而言，家庭護理設置領域的肺活量計市場預計將在2024 年和2032 年期間以10% 的複合年成長率產生可觀的收入。的日益重視。攜帶式和方便用戶使用的肺活量計提供的便利性和可及性使患者能夠方便地進行肺功能測試，而無需經常訪問醫療機構。

到 2032 年，亞太地區肺活量計行業規模將以 11.4% 的複合年成長率成長。許多亞洲國家的人口老化，加上生活方式和飲食習慣的改變，導致慢性阻塞性肺病和氣喘的盛行率升高。此外，旨在改善醫療基礎設施和提高呼吸健康意識的政府措施將刺激區域產業的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 呼吸道疾病盛行率上升
    • 設備技術進步
    • 人們越來越偏好家庭醫療保健
  • 產業陷阱與挑戰
    • 缺乏熟練的專業人員和報銷政策
• 成長潛力分析
• 監管環境
• 技術景觀
• 報銷場景
• 波特的分析
• PESTEL分析
• 未來市場趨勢

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

• 主要趨勢
• 裝置
  • 手持式
  • 桌上
  • 桌面
• 軟體
• 耗材及配件

第 6 章：市場估計與預測：按技術分類，2018 年 - 2032 年

• 主要趨勢
• 體積測量
• 流量測量
• 峰值流量計

第 7 章：市場估計與預測：按應用分類，2018 年 - 2032 年

• 主要趨勢
• 氣喘
• 慢性阻塞性肺病
• 囊腫纖維化
• 肺纖維化
• 其他應用

第 8 章：市場估計與預測：按最終用途，2018 - 2032 年

• 主要趨勢
• 醫院和診所
• 家庭護理設置
• 臨床實驗室
• 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• COSMED srl
• FUKUDA SANGYO CO., LTD.
• Geratherm Medical AG
• Hill-Rom Holdings, Inc. (Baxter International)
• Koninklijke Philips N.V.
• ndd Medical Technologies
• Schiller AG
• Sibelmed
• Teleflex Incorporated
• Vitalograph
• Vyaire Medical Inc.

Spirometer Market size is likely to record more than 9.6% CAGR from 2024 and 2032 propelled by the increasing prevalence of respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. As per WHO, COPD claims the lives of over 3 million individuals annually. With rising global awareness about the importance of early detection and management of respiratory conditions, healthcare providers are increasingly adopting spirometers as essential diagnostic tools. Moreover, the aging population worldwide is contributing to the market growth, as elderly individuals are more prone to respiratory ailments and require regular monitoring of the lung functions.

Furthermore, the growing emphasis on preventive healthcare and wellness initiatives is fostering the adoption of spirometry testing as a routine screening tool in various healthcare settings. The integration of spirometry into telemedicine platforms and electronic health records facilitates remote monitoring and data management for enhancing patient care and treatment outcomes. Government initiatives and healthcare policies aimed at improving respiratory healthcare infrastructure and promoting early disease detection will also help in driving the market growth.

The spirometer industry is classified based on product, technology, application, end-use and region.

By application, the market size from the pulmonary fibrosis segment will record a 9.7% growth rate through 2032. Early detection and monitoring of pulmonary function are crucial for managing the rising prevalence of pulmonary fibrosis effectively. Spirometry serves as a vital diagnostic tool for assessing lung functions and monitoring disease progression in pulmonary fibrosis patients. With growing awareness about the importance of regular pulmonary function testing in disease management, the demand for spirometers among healthcare providers specializing in respiratory care will continue to rise.

In terms of end-use, the spirometer market from the homecare settings segment is poised to generate substantial revenue at 10% CAGR during 2024 and 2032. The growth is favored by the increasing emphasis on remote patient monitoring and management of chronic respiratory conditions in the comfort of the homes of patients. The convenience and accessibility offered by portable and user-friendly spirometers enables patients to perform lung function tests conveniently without the need for frequent visits to healthcare facilities.

Asia Pacific spirometers industry size will grow at 11.4% CAGR through 2032. The rapid urbanization and industrialization is leading to increasing levels of air pollution and the subsequent rise in respiratory diseases. The aging population in many Asian countries, coupled with changing lifestyles and dietary habits is contributing to a higher prevalence COPD and asthma. Additionally, government initiatives aimed at improving healthcare infrastructure and raising awareness about respiratory health will stimulate the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of respiratory diseases
    • 3.2.1.2 Technological advancements in devices
    • 3.2.1.3 Growing preference for home healthcare
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of skilled professionals and reimbursement policies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Reimbursement scenario
• 3.7 Porter's analysis
  • 3.7.1 Supplier power
  • 3.7.2 Buyer power
  • 3.7.3 Threat of new entrants
  • 3.7.4 Threat of substitutes
  • 3.7.5 Industry rivalry
• 3.8 PESTEL analysis
• 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 Hand held
  • 5.2.2 Table top
  • 5.2.3 Desktop
• 5.3 Software
• 5.4 Consumables & accessories

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Volume measurement
• 6.3 Flow measurement
• 6.4 Peak flow meters

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Asthma
• 7.3 COPD
• 7.4 Cystic fibrosis
• 7.5 Pulmonary fibrosis
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Homecare settings
• 8.4 Clinical laboratories
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 COSMED srl
• 10.2 FUKUDA SANGYO CO., LTD.
• 10.3 Geratherm Medical AG
• 10.4 Hill-Rom Holdings, Inc. (Baxter International)
• 10.5 Koninklijke Philips N.V.
• 10.6 ndd Medical Technologies
• 10.7 Schiller AG
• 10.8 Sibelmed
• 10.9 Teleflex Incorporated
• 10.10 Vitalograph
• 10.11 Vyaire Medical Inc.